Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Next Previous
Trial Profile

An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Gastric cancer; Intestinal cancer; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms NELMAS

Most Recent Events

  • 14 Jan 2026 Status changed from recruiting to discontinued.
  • 09 Aug 2024 Planned number of patients changed from 90 to 106.
  • 09 Aug 2024 Planned End Date changed from 30 Dec 2028 to 30 Mar 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top